Elegen Corporation announced that it will receive $35,982,969 in funding on May 9, 2024. The company will issue common stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,593 GBX | -0.73% | -1.82% | +9.74% |
06-13 | REGENXBIO Inc. Announces Chief Executive Officer Changes | CI |
06-12 | Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,593 GBX | -0.73% | -1.82% | 82.98B | ||
129.8 USD | -0.55% | -2.35% | 37.89B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.74% | 82.98B | |
+41.20% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+17.51% | 246B | |
+0.16% | 225B | |
+10.39% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- Elegen Corporation announced a financing transaction